Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.

@article{Surakanti2008SalivaryGM,
  title={Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.},
  author={Sujani G Surakanti and Mark Agulnik},
  journal={Seminars in oncology},
  year={2008},
  volume={35 3},
  pages={309-19}
}
Salivary gland tumors are a rare and clinically diverse group of neoplasms that represent less than 1% of all malignancies. In locoregional recurrent or metastatic disease, systemic therapy is the standard approach. Numerous phase II studies with small sample sizes have assessed the activity of different cytotoxic agents, either alone or in combination. For these agents, the objective response rates are generally modest, ranging from 15% to 50%. Duration of response is typically cited in the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 82 references

Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study [abstract

  • JM Guigay, F Bidault, S Temam, F Janot, E Raymond, S. Faivre
  • J Clin Oncol,
  • 2007

A multicenter phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT)

  • M Agulnik, EE Cohen, RB Cohen, EX Chen, SJ Hotte, E Winquist
  • Ann Oncol
  • 2006

Preliminary results of a phase II trial on targeted therapy with cetuximab in EGFR-expressing adenoid cystic carcinoma of the oral cavity

  • E Hitre, A Boer, E Remenar, Z. Takacsi-Nagy
  • Ann Oncol
  • 2006

Similar Papers

Loading similar papers…